The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings : 85 % of patients in the dupilumab group , as compared with 35 % of those in the placebo group , had a 50 % reduction in the EASI score ( EASI-50 , with higher scores in the EASI indicating greater severity of eczema ) ( P < 0.001 ) ; 40 % of patients in the dupilumab group , as compared with 7 % in the placebo group , had a score of 0 to 1 ( indicating clearing or near-clearing of skin lesions ) on the investigator 's global assessment ( P < 0.001 ) ; and pruritus scores decreased ( indicating a reduction in itch ) by 55.7 % in the dupilumab group versus 15.1 % in the placebo group ( P < 0.001 ) .